Versatope Therapeutics, Inc., a biotechnology company developing vaccines and therapeutics, recently announced a Phase 1 Small Business and Innovation Award from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH) to develop a novel vaccine for the prevention and possible treatment for Clostridioides difficile, also known as C. diff.
Versatope is developing a universal influenza vaccine that has the potential to provide robust and durable immunity against multiple influenza. The company is now shifting gears in order to respond to the present pandemic. In September 2019, Versatope was one of 10 early-stage life sciences companies in Massachusetts to receive funding through the MLSC’s Milestone Achievement Program (MAP), which addresses the needs of early-stage life sciences companies by providing grant funding to execute critical, value-creating technical milestones.
